TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7786219

Group type: EXPERIMENTAL
Intervention: Vitrectomy surgery with long‐acting gas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitrectomy surgery with silicone oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative aphakia or pseudophakia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative iris neovascularization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reoperation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Absence of a fluid/gas exchange
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corneal touch by silicone oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Presence of aqueous cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Presence of aqueous flare
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corneal abnormalities
Number of subjects: 0
Study: 2223334

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg‐1
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 28
Study: 638961

Group type: EXPERIMENTAL
Intervention: Radical mastectomy
Number of subjects: 716

Group type: COMPARATOR
Intervention: Extended radical mastectomy
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N- (negative axillary nodes)
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N+ (positive axillary nodes)
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N+ 1-3 nodes
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N+ greater than 3 nodes
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N- IMN+ (internal mammary nodes positive)
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N+ IMN+ (internal mammary nodes positive)
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N-
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N+
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N- IMN+
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N+ IMN+
Number of subjects: 716
Study: 31731089

Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: hs-cTnT added to RIETE score
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: hs-cTnT log-unit increase
Number of subjects: 230

Group type: COMPARATOR
Intervention: RIETE score
Number of subjects: 230
Study: 31148473

Group type: EXPERIMENTAL
Intervention: Simple Daily Sweepstakes
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Deadline Sweepstakes
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Sweepstakes Plus Deposit Contract
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Wireless-enabled pill bottle and daily reminder messages
Number of subjects: 805
Study: 28602435

Group type: EXPERIMENTAL
Intervention: 1-stage bursectomy
Number of subjects: 164

Group type: COMPARATOR
Intervention: 2-stage bursectomy
Number of subjects: 164
Study: 26418007

Group type: EXPERIMENTAL
Intervention: Low contrast volume group (0.75 ml/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Routine contrast volume group (1.5 ml/kg)
Number of subjects: 34
Study: 24638015

Group type: EXPERIMENTAL
Intervention: Amrubicin plus cisplatin (AP)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Irinotecan plus cisplatin (IP)
Number of subjects: 284
Study: 21239131

Group type: EXPERIMENTAL
Intervention: Neutral enteral contrast (water)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Positive enteral contrast (2% water soluble iodinated contrast)
Number of subjects: 40
Study: 20646266

Group type: EXPERIMENTAL
Intervention: Conservative strategy with antibiotics: hospital admission, supportive measures, and at least 48 hours of intravenous antibiotics switched to oral for a total duration of 10 days.
Number of subjects: 533

Group type: COMPARATOR
Intervention: Liberal strategy without antibiotics: admission only if needed on clinical grounds, supportive measures only.
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Both strategies (antibiotics and no antibiotics)
Number of subjects: 533
Study: 17205556

Group type: EXPERIMENTAL
Intervention: Altered stiffness shoes
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Altered angle shoes
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo shoe
Number of subjects: 14
Study: 15919269

Group type: EXPERIMENTAL
Intervention: Epidural (EPI)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Intercostal nerve catheter plus patient-controlled analgesia (ICN-PCA)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study: 12411537

Group type: EXPERIMENTAL
Intervention: CHO (1 g (kg body mass)(-1) glucose 75 min prior to exercise)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 8
Study: 9283064

Group type: COMPARATOR
Intervention: Mibefradil 50 mg
Number of subjects: 307

Group type: COMPARATOR
Intervention: Mibefradil 100 mg
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 8437701

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Insight into psychogenic mechanisms
Number of subjects: 18
Study: 2940607

Group type: EXPERIMENTAL
Intervention: 2,500‐Hz sine‐wave electrical stimulation modulated at 50 bursts per second to the gastrocnemius muscle
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 14
Study: 30111065

Group type: EXPERIMENTAL
Intervention: Xiaoqinglong decoction combined with noninvasive ventilation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Western medicine combined with noninvasive ventilator therapy (Control group)
Number of subjects: 84
Study: 27311495

Group type: EXPERIMENTAL
Intervention: Buprenorphine (5 μg/h, titrated to a maximum of 40 μg/h)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 24833354

Group type: EXPERIMENTAL
Intervention: VMP plus siltuximab (11 mg/kg every 3 weeks)
Number of subjects: 106

Group type: COMPARATOR
Intervention: VMP
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: VMP plus siltuximab (S+VMP)
Number of subjects: 106
Study: 22452610

Group type: EXPERIMENTAL
Intervention: HIGH training load
Number of subjects: 7

Group type: COMPARATOR
Intervention: LOW training load
Number of subjects: 7
Study: 20505271

Group type: EXPERIMENTAL
Intervention: HTLV-1 infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recent studies on CD4 T cells
Number of subjects: 0
Study: 17594199

Group type: COMPARATOR
Intervention: TMP-SMX (7 patients)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Zidovudine plus TMP-SMX (5 patients)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Neither drug (5 patients)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Combination group (zidovudine plus TMP-SMX)
Number of subjects: 23

Group type: COMPARATOR
Intervention: TMP-SMX
Number of subjects: 23
Study: 16249848

Group type: EXPERIMENTAL
Intervention: Seprafilm (SEPRA+)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No Seprafilm (SEPRA‐)
Number of subjects: 62
Study: 12401599

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg/kg, maximum 4 mg (Group 1)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Dolasetron 0.5 mg/kg, maximum 25 mg (Group 2)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Saline placebo (Group 3)
Number of subjects: 149
Study: 10023504

Group type: EXPERIMENTAL
Intervention: 25 mg i.v. clomipramine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10-week oral clomipramine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10-week oral fluvoxamine
Number of subjects: 50
Study: 7587726

Group type: EXPERIMENTAL
Intervention: HIV+ patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 1955308

Group type: EXPERIMENTAL
Intervention: 5 mg yohimbine per os 4 times a day for 3 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 15 mg yohimbine per os
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6763456

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conray 60 (iothalamate meglumine)
Number of subjects: 0
Study: 30862384

Group type: COMPARATOR
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both PTNS and TTNS
Number of subjects: 24
Study: 29883769

Group type: EXPERIMENTAL
Intervention: Oral omega-3 (ω3) supplementation
Number of subjects: 0
Study: 26293358

Group type: EXPERIMENTAL
Intervention: Blunted heart rate response (HRR) to regadenoson stress myocardial perfusion imaging (MPI)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Normal heart rate response (HRR) to regadenoson stress myocardial perfusion imaging (MPI)
Number of subjects: 303
Study: 24914003

Group type: EXPERIMENTAL
Intervention: Soapy water (30 g powdered detergent in 1.5 L water)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bar soap
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 0
Study: 21993999

Group type: EXPERIMENTAL
Intervention: Electronic alerts recommending performance of an electrocardiogram and administration of aspirin for high risk patients (FRS ≥ 10%)
Number of subjects: 7083

Group type: EXPERIMENTAL
Intervention: Electronic alerts recommending against performance of cardiac stress testing for low risk patients (FRS < 10%)
Number of subjects: 7083

Group type: COMPARATOR
Intervention: High risk patients evaluated in the emergency department
Number of subjects: 7083

Group type: COMPARATOR
Intervention: High risk patients hospitalized
Number of subjects: 7083

Group type: COMPARATOR
Intervention: Acute myocardial infarction occurrence
Number of subjects: 7083
Study: 19755409

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17324155

Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (LDD) for 3 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (placebo) for 3 months
Number of subjects: 34
Study: 15210651

Group type: EXPERIMENTAL
Intervention: GG genotype hypertensive subjects
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: AA/AG genotype hypertensive subjects
Number of subjects: 140
Study: 11390534

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 6262
Study: 9715839

Group type: EXPERIMENTAL
Intervention: Acute methadone treatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chronic methadone treatment
Number of subjects: 8
Study: 7978183

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Methohexitone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 51
Study: 2491026

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 60
Study: 1107769

Group type: EXPERIMENTAL
Intervention: Alprenolol slow-release formulation (Aptin Durules) 400-800 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alprenolol ordinary tablets (Aptin) 400 mg per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alprenolol slow-release formulation (Aptin Durules) double dosage
Number of subjects: 0
Study: 31464960

Group type: EXPERIMENTAL
Intervention: DEX (1 μg·kg for 10 minutes, then adjusted to 0.2‐0.7 μg·kg·hour)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: DEX (0.5 μg·kg for 10 minutes, then adjusted to 0.2‐0.7 μg·kg·hour)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Sufentanil (0.3 μg·kg for 10 minutes, then adjusted to 0.2‐0.4 μg·kg·hour)
Number of subjects: 196
Study: 28052014

Group type: EXPERIMENTAL
Intervention: MET overexpression (IHC 3+)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: HER2 overexpression (IHC 3+)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: MET overexpression in HER2 positive patients
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Correlation between MET overexpression and clinical stages
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Correlation between MET overexpression and pathologic stages
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Concordance rate between MET overexpression and gene amplification
Number of subjects: 816
Study: 26583670

Group type: EXPERIMENTAL
Intervention: Extracapsular lymph node involvement (EC‐LNI)
Number of subjects: 1639

Group type: COMPARATOR
Intervention: Intracapsular lymph node involvement (IC‐LNI)
Number of subjects: 1639

Group type: COMPARATOR
Intervention: pN1 IC‐LNI
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: pN1 EC‐LNI
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: pN2 EC‐LNI
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: pN3 EC‐LNI
Number of subjects: 1639
Study: 24127952

Group type: EXPERIMENTAL
Intervention: 200 mg vaginal progesterone daily until delivery
Number of subjects: 52

Group type: COMPARATOR
Intervention: No therapy or placebo
Number of subjects: 52
Study: 21981704

Group type: EXPERIMENTAL
Intervention: Montessori intervention
Number of subjects: 29

Group type: COMPARATOR
Intervention: Routine activities
Number of subjects: 29
Study: 18494605

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) WBC count > or = 102 cells/microL
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Interleukin-10 (IL-10) concentrations > or = 37 pg/mL
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: LATEX/IgM end titers > or = 1:32
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: LATEX/T. b. gambiense end titers > or = 1:2
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Total protein concentrations > or = 674 mg/L
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: CSF WBC counts < or = 5 cells/microL (6 months after treatment)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: CSF WBC count > or = 8 cells/microL and LATEX/IgM end titer > or = 1:4 (12 months after treatment)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: CSF WBC count > or = 8 cells/microL and LATEX/IgM end titer > or = 1:4 (18 and 24 months after treatment)
Number of subjects: 260
Study: 17002722

Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg single dose) plus iron supplements (60 mg elemental iron daily)
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Placebo plus iron supplements
Number of subjects: 1042
Study: 12690946

Group type: EXPERIMENTAL
Intervention: Applied muscle tension after watching a 2-min instructional video
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Applied muscle tension
Number of subjects: 37

Group type: COMPARATOR
Intervention: Untreated donors
Number of subjects: 37

Group type: COMPARATOR
Intervention: More experienced blood donors
Number of subjects: 37
Study: 10932486

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8966351

Group type: EXPERIMENTAL
Intervention: dehydrobenzperidol (1.25 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: metoclopramide (10 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ondansetron (4 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo (2 ml saline)
Number of subjects: 100
Study: 1342886

Group type: EXPERIMENTAL
Intervention: Micronized, freeze-dried DP extract in powder (active therapy)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lactose capsules (placebo group)
Number of subjects: 24
Study: 3871188

Group type: EXPERIMENTAL
Intervention: Prednisone 60 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Prednisone 20 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) aerosol 336 micrograms
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: BDP vehicle
Number of subjects: 25
Study: 31798892

Group type: EXPERIMENTAL
Intervention: Trimethylamine N-oxide (TMAO) levels
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (matched by age, sex, and treatment arm)
Number of subjects: 330
Study: 30096932

Group type: EXPERIMENTAL
Intervention: Horticultural Therapy (HT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 59
Study: 27348909

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with moxibustion plaster
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electroacupuncture (EA)
Number of subjects: 60
Study: 24825870

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis
Number of subjects: 312
Study: 22189593

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray (FP) 100 mcg twice daily as initial treatment with Fexofenadine hydrochloride tablet (FEX) 60 mg twice daily as additional treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Fexofenadine hydrochloride tablet (FEX) 60 mg twice daily as initial treatment with Fluticasone propionate nasal spray (FP) 100 mcg twice daily as additional treatment
Number of subjects: 51
Study: 20348976

Group type: EXPERIMENTAL
Intervention: Drain used in group A (35 patients)
Number of subjects: 67

Group type: COMPARATOR
Intervention: No drain used in group B (32 patients)
Number of subjects: 67
Study: 18388769

Group type: EXPERIMENTAL
Intervention: Canine fossa puncture (CFP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Maxillary sinus clearance through middle meatal antrostomy (MMA)
Number of subjects: 24
Study: 16092049

Group type: EXPERIMENTAL
Intervention: Patients with poorly controlled diabetes
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy volunteers (control)
Number of subjects: 28
Study: 12410456

Group type: EXPERIMENTAL
Intervention: Drain suction
Number of subjects: 116

Group type: COMPARATOR
Intervention: No drain suction
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study: 10511346

Group type: EXPERIMENTAL
Intervention: Combined estradiol‐progestogen (2 mg estradiol + 0.5 mg trimegestone or 10 mg dydrogesterone)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Unopposed estradiol (2 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 7495242

Group type: EXPERIMENTAL
Intervention: beta‐carotene, alpha‐tocopherol, and selenium
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: multiple vitamin‐mineral supplementation
Number of subjects: 30000
Study: 1742667

Group type: EXPERIMENTAL
Intervention: Dilatable pulmonary artery banding prosthesis
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fixed fabric bands
Number of subjects: 19
Study: 7176845

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 148

Group type: COMPARATOR
Intervention: Immunosuppressive treatment
Number of subjects: 148
Study: 31621936

Group type: EXPERIMENTAL
Intervention: Current use of any antiepileptic drug
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: Current use of any antiepileptic drug in individuals with a history of suicidal behavior
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: Current use of any antiepileptic drug in individuals without a history of suicidal behavior
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: Current use of any antiepileptic drug in individuals with a familial predisposition to psychiatric disorders
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: Current use of any antiepileptic drug in individuals without a familial predisposition to psychiatric disorders
Number of subjects: 1759
Study: 27672124

Group type: EXPERIMENTAL
Intervention: PF‐04236921 10 mg
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: PF‐04236921 50 mg
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: PF‐04236921 200 mg
Number of subjects: 183
Study: 25930037

Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning (CEP)
Number of subjects: 1622

Group type: COMPARATOR
Intervention: Resources for Services (RS)
Number of subjects: 1622
Study: 23968157

Group type: COMPARATOR
Intervention: CHF5074 (600 mg/day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: CHF5074 (200 mg/day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: CHF5074 (400 mg/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CHF5074 (dose-dependent)
Number of subjects: 96
Study: 21849078

Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 0
Study: 19142656

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) and Glycerol (Gly) supplementation (20 g Cr and 2 g Gly per kg body mass plus 2 l of water)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Water alone (Pl)
Number of subjects: 19
Study: 16489526

Group type: EXPERIMENTAL
Intervention: High-dose melphalan (200 mg/m(2)) and autologous blood stem-cell support
Number of subjects: 6

Group type: COMPARATOR
Intervention: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) alone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cyclophosphamide (2-4 g/m(2)) and rhG-CSF
Number of subjects: 6
Study: 15291211

Group type: EXPERIMENTAL
Intervention: Emotional support group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Informational support group
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-support group (control)
Number of subjects: 24
Study: 10932515

Group type: EXPERIMENTAL
Intervention: DM‐T (n = 7)
Number of subjects: 61

Group type: COMPARATOR
Intervention: DM‐C (n = 21)
Number of subjects: 61
Study: 9032543

Group type: EXPERIMENTAL
Intervention: Sabal serrulata extract IDS 89 (Strogen) 320 mg/capsule, 3 x 2 capsules daily for 3 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8495772

Group type: EXPERIMENTAL
Intervention: IVF treatment (one cycle)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group (wait for 6 months before IVF)
Number of subjects: 245
Study: 2825571

Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control
Number of subjects: 79